DaVita (NYSE:DVA) Announces Quarterly Earnings Results

DaVita (NYSE:DVA) announced its quarterly earnings results on Tuesday. The company reported $4.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.88 by $0.14, FiscalAI reports. DaVita had a net margin of 6.05% and a negative return on equity of 231.38%. The firm had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.50 billion. During the same quarter last year, the firm posted $2.95 EPS. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. DaVita updated its FY 2026 guidance to 14.100-15.200 EPS.

Here are the key takeaways from DaVita’s conference call:

• DaVita reaffirmed its 2026 guidance, including adjusted operating income of $2.2 billion at the midpoint and adjusted EPS of $14.65. Management expects fourth-quarter adjusted operating income to exceed third-quarter results by $50 million to $100 million, primarily due to IKC timing.
• Treatment-volume growth accelerated, supported by sustained improvements in patient mortality. DaVita now expects 2026 treatment growth near the top of its prior 25–50 basis-point range, or roughly 50–75 basis points after normalizing for calendar effects.
• DaVita plans to broadly deploy expanded hemodialysis using Nipro’s newly approved medium cut-off dialyzer in the coming quarters. The technology is compatible with existing machines, supply has been secured, and management believes any meaningful financial upside from lower mortality would begin around 2028.
• Revenue per treatment declined sequentially because of lower commercial insurance mix following the expiration of ACA subsidies and reduced phosphate-binder revenue. Management continues to estimate a roughly $40 million 2026 headwind from commercial-mix changes, potentially increasing to $70 million in 2027.
• The transition of phosphate binders into the Medicare bundle has reduced reliance on less-effective over-the-counter treatments by more than 50%, while lowering DaVita’s related revenue and costs. Management supports the policy and expects the final 2027 ESRD payment rule to determine the ultimate financial impact.

DaVita Price Performance

Shares of DVA stock traded down $7.70 on Thursday, hitting $180.99. 895,360 shares of the stock traded hands, compared to its average volume of 960,142. DaVita has a 52 week low of $101.00 and a 52 week high of $247.49. The firm has a 50 day simple moving average of $218.97 and a two-hundred day simple moving average of $175.94. The firm has a market cap of $11.62 billion, a price-to-earnings ratio of 14.77, a PEG ratio of 0.75 and a beta of 0.88.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Barclays lifted their target price on shares of DaVita from $218.00 to $224.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Truist Financial raised their price target on DaVita from $205.00 to $250.00 and gave the stock a “hold” rating in a research note on Tuesday, July 14th. UBS Group upped their price objective on DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, July 10th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $265.00 target price on shares of DaVita in a research report on Wednesday. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of DaVita in a research note on Monday, June 8th. Two investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $225.00.

Insiders Place Their Bets

In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the sale, the insider directly owned 109,194 shares of the company’s stock, valued at $22,756,029.60. This trade represents a 12.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.90% of the company’s stock.

Institutional Trading of DaVita

Institutional investors have recently made changes to their positions in the business. Atlas Capital Advisors Inc. bought a new stake in DaVita in the fourth quarter worth $139,000. Smartleaf Asset Management LLC grew its stake in shares of DaVita by 66.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 753 shares of the company’s stock worth $86,000 after buying an additional 301 shares in the last quarter. Gen Wealth Partners Inc grew its stake in shares of DaVita by 10.0% in the 4th quarter. Gen Wealth Partners Inc now owns 880 shares of the company’s stock worth $100,000 after buying an additional 80 shares in the last quarter. Zions Bancorporation National Association UT increased its holdings in shares of DaVita by 533.1% in the 4th quarter. Zions Bancorporation National Association UT now owns 1,032 shares of the company’s stock worth $117,000 after buying an additional 869 shares during the last quarter. Finally, Advisory Services Network LLC purchased a new stake in shares of DaVita during the 3rd quarter valued at about $115,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita News Roundup

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: DaVita reported second-quarter adjusted earnings of $4.02 per share, above the roughly $3.88–$4.01 analyst consensus, while revenue of $3.554 billion also exceeded expectations and rose 5.2% year over year. Adjusted operating income was $579 million and free cash flow reached $256 million. DaVita Second-Quarter 2026 Results
• Positive Sentiment: Management highlighted clinical-led treatment-volume growth, improved access to certain therapies and continued strategic execution. Barclays raised its price target from $218 to $224, although it maintained an “equal weight” rating. DVA Q2 Earnings Call Centers on Clinical-Led Volume Growth
• Neutral Sentiment: Unusually heavy call-option activity indicated increased speculative interest, with 9,484 calls traded versus a typical volume of about 1,428. This signals positioning but does not establish a fundamental direction.
• Neutral Sentiment: A value-focused Zacks review is examining DaVita’s earnings estimates, revisions, valuation, growth and momentum factors; no specific new rating or estimate change was provided. Is DaVita a Great Value Stock Right Now?
• Negative Sentiment: Despite the earnings beat, DaVita left full-year 2026 adjusted EPS guidance unchanged at $14.10–$15.20, potentially disappointing investors who expected another increase. The midpoint is below the approximately $14.85 consensus estimate.
• Negative Sentiment: U.S. dialysis revenue per treatment declined sequentially to $415.87 from $417.59, pressured by payer-mix changes and normal fluctuations. Narrower margins, a weaker commercial mix and higher general and administrative expenses added to concerns about profitability. DaVita Stock Down Despite Q2 Earnings Beat

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.